Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation

被引:44
作者
Caliskan, Y. [1 ]
Besisik, S. K.
Sargin, D.
Ecder, T.
机构
[1] Istanbul Univ, Sch Med, Dept Internal Med, Div Nephrol, TR-34390 Istanbul, Turkey
[2] Istanbul Univ, Sch Med, Dept Internal Med, Div Hematol,Bone Marrow Transplantat Unit, TR-34390 Istanbul, Turkey
关键词
stem cell transplantation; renal dysfunction; sepsis; cyclosporine A;
D O I
10.1038/sj.bmt.1705412
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Renal insufficiency is a common complication early after hematopoietic stem cell transplantation ( HSCT). Renal function as measured by creatinine clearance (CrCl) was prospectively evaluated in 47 patients undergoing allogeneic (n = 22) or autologous (n = 25) HSCT during the first 100 days. Renal dysfunction was classified as follows: Grade 0 (< 25% decline in CrCl), Grade 1 (>= 25% decline in CrCl but < 2 x increase in serum creatinine), Grade 2 (>= 2 x rise in serum creatinine but no need for dialysis) and Grade 3 (>= 2 x rise in serum creatinine and need for dialysis). Thirty-three patients (70%) had Grade 1-3 renal dysfunction. Renal dysfunction was more common after myeloablative allogeneic HSCT (91%) than autologous HSCT (52%) (P = 0.004), and was associated with a high risk of mortality (P = 0.039). Sepsis in autologous HSCT patients and cyclosporine toxicity in allogeneic HSCT patients were associated with renal dysfunction. We conclude that autologous and allogeneic HSCT differ in the likelihood and causes of renal dysfunction.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 26 条
[1]  
ATKINSON K, 1990, TRANSPLANT P, V22, P1331
[2]   DYNAMICS OF GLOMERULAR ULTRAFILTRATION .9. EFFECTS OF PLASMA-PROTEIN CONCENTRATION [J].
BAYLIS, C ;
ICHIKAWA, I ;
WILLIS, WT ;
WILSON, CB ;
BRENNER, BM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1977, 232 (01) :F58-F71
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   Renal failure after bone-marrow transplantation [J].
Cohen, EP .
LANCET, 2001, 357 (9249) :6-7
[5]  
CONTRERAS AM, 1994, REV INVEST CLIN, V46, P37
[6]   RENAL DYSFUNCTION DURING HIGH-DOSE CISPLATIN THERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION - EFFECT OF AMINOGLYCOSIDE THERAPY [J].
COOPER, BW ;
CREGER, RJ ;
SOEGIARSO, W ;
MACKAY, WL ;
LAZARUS, HM .
AMERICAN JOURNAL OF MEDICINE, 1993, 94 (05) :497-504
[7]   Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation [J].
El Seisi, S ;
Gupta, R ;
Clase, CM ;
Forrest, DL ;
Milandinovic, M ;
Couban, S .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (11) :683-688
[8]   Hematopoietic stem cell transplantation for hematological malignancies in Europe [J].
Gratwohl, A ;
Baldomero, H ;
Passweg, J ;
Frassoni, F ;
Niederwieser, D ;
Schmitz, N ;
Urbano-Ispizua, A .
LEUKEMIA, 2003, 17 (05) :941-959
[9]   ACUTE-RENAL-FAILURE IN PATIENTS FOLLOWING BONE-MARROW TRANSPLANTATION - PREVALENCE, RISK-FACTORS AND OUTCOME [J].
GRUSS, E ;
BERNIS, C ;
TOMAS, JF ;
GARCIACANTON, C ;
FIGUERA, A ;
MOTELLON, JL ;
PARAISO, V ;
TRAVER, JA ;
FERNANDEZRANADA, JM .
AMERICAN JOURNAL OF NEPHROLOGY, 1995, 15 (06) :473-479
[10]   Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation [J].
Herget-Rosenthal, S ;
Uppenkamp, M ;
Beelen, D ;
Kohl, D ;
Kribben, A .
NEPHRON, 2000, 84 (02) :136-141